Skip to main content

Table 4 Comparisons of the performance indicators between two brands of pepsinogen testing using the logistic regression models

From: Brand interchangeability of pepsinogen tests in the real-world setting after eradication of Helicobacter pylori: a community-based study

Model*

Odds ratio

95% CI

Positive predictive value for atrophic gastritis

 Model 1

  Test 1 vs. Test 2

1.00

0.42–2.38

 Model 2

  Test 1 vs. Test 2

1.12

0.40–3.12

  Age ≥ 50 vs. 30–49 years

3.68

0.67–20.16

  Male vs. female

1.11

0.34–3.61

Positive predictive value for intestinal metaplasia

 Model 1

  Test 1 vs. Test 2

1.16

0.54–2.48

 Model 2

  Test 1 vs. Test 2

1.75

0.65–4.67

  Age ≥ 50 vs. 30–49 years

5.97

1.12–31.77†

  Male vs. female

2.84

0.94–8.55

Detection rate for atrophic gastritis

 Model 1

  Test 1 vs. Test 2

1.00

0.45–2.23

 Model 2

  Test 1 vs. Test 2

1.00

0.45–2.24

  Age ≥ 50 vs. 30–49 years

5.61

1.30–24.15†

  Male vs. female

1.37

0.58–3.25

Detection rate for intestinal metaplasia

 Model 1

  Test 1 vs. Test 2

1.13

0.57–2.21

 Model 2

  Test 1 vs. Test 2

1.20

0.60–2.40

  Age ≥ 50 vs. 30–49 years

8.91

2.12–37.51†

  Male vs. female

2.23

1.01–4.96†

  1. CI, confidence interval; Test 1, GastroPanel (Biohit HealthCare, Helsinki, Finland); Test 2, LZ-Test (Eiken Chemical Co., Ltd, Tokyo, Japan)
  2. *Model 1: the univariate logistic regression model; model 2: the multivariate logistic regression model also adjusted for body mass index, social habits, and the medical histories, in addition to the age and sex
  3. †P < 0.05